JPRN-UMIN000019164已完成未知
Efficacy and Safety of Low Dose Prasugrel in Japanese Acute Coronary Syndrome Patients: A Single-center Prospective Clinical Trial - Efficacy and Safety of Low Dose Prasugrel
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) bleeding patients (hemophilia, cerebral bleeding, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, or vitreous hemorrhage) (2) hypersensitive patients for prasugrel in past times (Relative exclusion criteria) (1) patients with cerebral bleeding or critical bleeding (BARC classification 3 or greater) (2) patients with past history of cerebral infarction or transient ischemic attack (3) patients with anticoagulant therapy or scheduled for anticoagulant therapy (4) patients with thienopyridine therapy already
研究者
相似试验
已完成
不适用
Effectiveness and safety of Satralizumab in Japan; Interleukin-6 receptor inhibition in Neuromyelitis Optica Spectrum Disorders, multicentre medical chart revieweuromyelitis optica spectrum disorderJPRN-UMIN000050027CHUGAI PHARMACEUTICAL CO., LTD.120
已完成
4 期
Safety and eficity of 2.5mg prasugrel therapy in the eldely or low body weight Japanese patients undergoing percutaneous coronary interventioIschemic Heart DiseaseJPRN-UMIN000019424Chiba University Hospital70
进行中（未招募）
1 期
Study of Prasugrel in Children who have Sickle Cell Diseasesickle cell diseaseEUCTR2017-001243-12-Outside-EU/EEAEli Lilly and Company Limited33
已完成
不适用
The effects of Prasugrel on pharmacokinetics and pharmacodynamics of EdoxabaOnly healthy subjectsJPRN-jRCTs071190006Ikushima Ippei24
进行中（未招募）
不适用
Safety and Efficacy Study of BP-DPC18 for the treatment of Femoropopliteal Artery Lesions in Japaatherosclerotic diseaseJPRN-jRCT2072200103Soga Yoshimitsu120